A carregar...
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
BACKGROUND: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. PATIENTS AND METHODS: Patients with histologically confirmed progressive CRP...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6301292/ https://ncbi.nlm.nih.gov/pubmed/30588025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S174206 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|